Delivery Order SPE2DB20D2104-SPE2DB24FMBEQ

Award Date 9/10/24
Potential Completion Date 9/11/24
Potential Value $8.1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award from the Defense Logistics Agency (DLA) was issued to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, to deliver Contrave ER 8-90 mg tablets. The $4,090.31 firm fixed-price delivery order has an ultimate completion date of October 26, 2023 and is not designated as a set-aside contract. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical division, which serves as a primary vehicle for providing a...
This federal contract award is to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) for the delivery of the drug Contrave ER 8-90 mg tablets. The delivery order, valued at $5,367.46, is a firm-fixed-price contract with an ultimate completion date of October 24, 2024. Amerisourcebergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Contrave ER 8-90 mg tablets. The award is valued at $10,607.04 and has a period of performance through November 2024. The contract is a Firm Fixed Price Delivery Order and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a broader $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Contrave ER 8-90 mg tablets. The firm-fixed-price, $2,970.63 delivery order contract has an ultimate completion date of December 5, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $27,007.04, is for the delivery of the drug Contrave ER 8-90 mg tablets. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $13,196.27 Firm Fixed Price delivery order is for the supply of Contrave ER 8-90 mg tablets. The contract has a period of performance through September 16, 2024 and was awarded on September 13, 2024. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is a delivery order for the supply of CONTRAVE ER 8-90 MG TABLET 120S. The total ceiling value of the contract is $4,604.61, with a completion date of October 25, 2024. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and is a firm fixed-price delivery order with no set-aside designation. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Contrave ER 8-90 mg tablets. The $12,031.15 firm fixed price contract has a performance period through July 15, 2024 and is not associated with a set-aside requirement. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to provide a comprehensive range of pharmaceutical...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $19,825.61 firm fixed-price delivery order is for the supply of Contrave ER 8-90 mg tablets, a medication used for weight management. The contract has an ultimate completion date of July 19, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, is a delivery order valued at $11,974.28 with a completion date of June 18, 2024. The award was made by the Defense Logistics Agency (DLA), a defense agency, for the supply of the drug Contrave ER 8-90 mg tablet. The contract has no set-aside designation, indicating open competition. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through...
  • SPE2DB20D2104
    Indefinite Delivery Contract
  • SPE2DB20D2104-SPE2DB24FMBEQ
    Delivery Order

This federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, is for the delivery of Contrave ER 8-90 mg tablet 120s. The contract, valued at $8,056.77, is a delivery order awarded by the Defense Logistics Agency (DLA), a defense agency. The award has a completion date of September 11, 2024 and is a firm fixed-price contract.

The contract is a child of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs.

The contract does not have a set-aside designation, indicating it was open to full and open competition.

Generated 2/27/25, 10:54 AM